OverviewSuggest Edit

Adaptive Biotechnologies is a company developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its main product, immunoSEQ, uses a proprietary immune profiling assay to analyze T cells and B cells, critical components of the adaptive immune system’s defense against disease. The company develops a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. 

TypePublic
Founded2009
HQSeattle, WA, US
Websiteadaptivebiotech.com
Employee Ratings3.7
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)453(+31%)
Revenue (FY, 2019)$85.1 M(+53%)
Share Price (Feb 2021)$61.4
Cybersecurity ratingDMore

Key People/Management at Adaptive Biotechnologies

Chad Cohen

Chad Cohen

Chief Financial Officer
Nancy Hill

Nancy Hill

Executive Vice President, Operations & Program Management
Harlan Robins

Harlan Robins

Chief Scientific Officer & Co-Founder
Chad Robins

Chad Robins

Chief Executive Officer, Co-Founder, Chairman of the Board
Stacy Taylor

Stacy Taylor

Senior Vice President, General Counsel
Lance Baldo

Lance Baldo

Chief Medical Officer
Show more

Adaptive Biotechnologies Office Locations

Adaptive Biotechnologies has offices in Seattle, New York and South San Francisco
Seattle, WA, US (HQ)
1551 Eastlake Ave E #200
New York, NY, US
1460 Broadway
South San Francisco, CA, US
2 Tower Pl UNIT 900
Show all (3)

Adaptive Biotechnologies Financials and Metrics

Adaptive Biotechnologies Revenue

Embed Graph
View revenue for all periods
Adaptive Biotechnologies's revenue was reported to be $85.07 m in FY, 2019
USD

Revenue (Q3, 2020)

26.3m

Gross profit (Q3, 2020)

20.2m

Gross profit margin (Q3, 2020), %

77%

Net income (Q3, 2020)

(36.7m)

EBIT (Q3, 2020)

(37.0m)

Market capitalization (8-Feb-2021)

8.4b

Closing stock price (8-Feb-2021)

61.4

Cash (30-Sept-2020)

497.1m

EV

7.9b
Adaptive Biotechnologies's current market capitalization is $8.4 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

38.4m55.7m85.1m

Revenue growth, %

45%

Cost of goods sold

15.7m19.7m22.3m

Gross profit

22.8m36.0m62.8m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

22.1m26.1m20.9m21.0m26.3m

Cost of goods sold

5.7m5.6m5.3m4.9m6.1m

Gross profit

16.4m20.5m15.6m16.1m20.2m

Gross profit Margin, %

74%79%74%77%77%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

83.3m55.0m96.6m

Accounts Receivable

5.6m4.8m12.7m

Prepaid Expenses

2.7m3.1m14.1m

Inventories

4.8m7.8m9.1m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

48.5m74.9m212.7m365.4m497.1m

Accounts Receivable

7.3m9.3m9.4m7.9m11.9m

Prepaid Expenses

4.0m10.0m9.6m10.7m19.7m

Inventories

8.0m8.7m10.5m10.5m10.7m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(42.8m)(46.4m)(68.6m)

Depreciation and Amortization

5.8m6.0m1.7m

Inventories

(2.7m)(3.0m)(1.2m)

Accounts Payable

(1.5m)2.2m6.1m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(34.0m)(48.0m)(31.4m)(64.9m)(101.7m)

Depreciation and Amortization

3.7m5.7m2.0m4.0m6.1m

Inventories

(166.0k)(829.0k)(1.4m)(1.5m)(1.7m)

Accounts Payable

1.3m3.1m(4.6m)(1.9m)30.0k
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Adaptive Biotechnologies Operating Metrics

FY, 2018

Immune Receptors Characteristics in Database

20 b

Partners

125

Product Lines

2
Show all operating metrics

Adaptive Biotechnologies Revenue Breakdown

Embed Graph

Adaptive Biotechnologies revenue breakdown by business segment: 59.2% from Sequencing revenue and 40.8% from Development revenue

Adaptive Biotechnologies Cybersecurity Score

Cybersecurity ratingPremium dataset

D

68/100

SecurityScorecard logo

Adaptive Biotechnologies Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Adaptive Biotechnologies Online and Social Media Presence

Embed Graph

Adaptive Biotechnologies Company Culture

  • Overall Culture

    B

    77/100

  • CEO Rating

    A+

    90/100

  • Compensation

    C-

    60/100

  • Diversity

    C

    69/100

Learn more on Comparably

Adaptive Biotechnologies News and Updates

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial …

Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting

MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may …

Adaptive Biotechnologies Leverages Microsoft Azure In Search For COVID-19 Answers

Adaptive Biotechnologies is working with Microsoft and using Azure Cloud to conduct research into the relationship of T cells to effectively fighting the COVID-19 pandemic.

Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration with Glax…

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial r…

Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2

Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials
Show more

Adaptive Biotechnologies Blogs

New T-Detect COVID test shows the power of combining Adaptive’s Immune Medicine Platform with Microsoft’s AI and machine learning

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Chad Robins, CEO Imagine if a simple blood test could provide accurate and early diagnosis of thousands of different diseases simultaneously? That is no easy task, but it may be possible using new technology that…

Adaptive President Julie Rubinstein Reflects on World Cancer Day

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Julie Rubinstein, President Eighteen years ago, I began a journey with my dad that profoundly impacted me personally and professionally. At the time, I was expecting my oldest daughter Emily when my healthy and a…

Learnings from the COVID-19 Immune Response Will Accelerate Healthcare Innovation

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Lance Baldo, Chief Medical Officer It has been about one year since SARS-CoV-2 hit the U.S. and, in that time, there have been over 100M reported cases and over 2M deaths globally. As the world races to develop s…

Powering the Age of Immune Medicine

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Chad Robins, CEO Ten years ago, my brother Harlan and I started Adaptive Biotechnologies on the premise that if we could read the genetic language that tells us how the adaptive immune system detects and treats d…

The Future of Immune Medicine

Adaptive is powering the age of immune medicine and propelling a paradigm shift in healthcare. The combination of our unique approach and the near-infinite applications of immune medicine provide opportunities to make a difference in the lives of people living with many different diseases, both now …
Show more

Adaptive Biotechnologies Frequently Asked Questions

  • When was Adaptive Biotechnologies founded?

    Adaptive Biotechnologies was founded in 2009.

  • Who are Adaptive Biotechnologies key executives?

    Adaptive Biotechnologies's key executives are Chad Cohen, Nancy Hill and Harlan Robins.

  • How many employees does Adaptive Biotechnologies have?

    Adaptive Biotechnologies has 453 employees.

  • What is Adaptive Biotechnologies revenue?

    Latest Adaptive Biotechnologies annual revenue is $85.1 m.

  • What is Adaptive Biotechnologies revenue per employee?

    Latest Adaptive Biotechnologies revenue per employee is $187.8 k.

  • Who are Adaptive Biotechnologies competitors?

    Competitors of Adaptive Biotechnologies include Proteus Digital Health, Juno Therapeutics and Takeda Pharmaceutical.

  • Where is Adaptive Biotechnologies headquarters?

    Adaptive Biotechnologies headquarters is located at 1551 Eastlake Ave E #200, Seattle.

  • Where are Adaptive Biotechnologies offices?

    Adaptive Biotechnologies has offices in Seattle, New York and South San Francisco.

  • How many offices does Adaptive Biotechnologies have?

    Adaptive Biotechnologies has 3 offices.